Literature DB >> 9649352

Pharmacokinetics of (R,S)-Albuterol after aerosol inhalation in healthy adult volunteers.

P J Anderson1, X Zhou, P Breen, L Gann, T W Logsdon, C M Compadre, F C Hiller.   

Abstract

The pharmacokinetics of inhaled (R,S)-albuterol following pulmonary absorption were studied in healthy human subjects. Ten subjects (5 females and 5 males) inhaled two puffs (180 microg) of albuterol via a metered-dose inhaler and spacer device. All subjects were nonsmoking and had normal pulmonary function. Charcoal slurries were ingested to block gastrointestinal absorption of drug. Venous samples were obtained from each subject at thirteen time points from 0 through 12 h post dose. (R,S)-Albuterol concentration in plasma was measured using a gas chromatography-mass spectrometry (GC-MS) assay. The plasma concentration-time profiles conformed to a two-compartment extravascular model with first-order absorption kinetics. The drug levels reached maximum in 12.6 +/- 2.2 (SD) minutes, which is in contrast with previous reports that maximum plasma concentrations occur within 2 to 4 h. The mean peak plasma level was 1469 +/- 410 pg/mL. The mean half-life of distribution was 17.9 +/- 8.2 min. The mean half-life of elimination was 4.4 +/- 1.5 h. Female subjects achieved peak concentration more rapidly than male subjects (10.4 vs 14.8 min, p = 0.01) and had a higher mean peak concentration (1778 vs 1159 pg/mL, p = 0.04).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649352     DOI: 10.1021/js970445u

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Age dependent systemic exposure to inhaled salbutamol.

Authors:  Klaus Bønnelykke; Jakob Jessing Jespersen; Hans Bisgaard
Journal:  Br J Clin Pharmacol       Date:  2007-03-01       Impact factor: 4.335

Review 2.  Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.

Authors:  Jens Markus Borghardt; Benjamin Weber; Alexander Staab; Charlotte Kloft
Journal:  AAPS J       Date:  2015-04-07       Impact factor: 4.009

Review 3.  The pharmacokinetics of levosalbutamol: what are the clinical implications?

Authors:  D W Boulton; J P Fawcett
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

4.  Haemodynamic responses to salbutamol and isometric exercise are altered in young adults with mild asthma.

Authors:  W Stephen Waring; Rachel B Leigh
Journal:  Eur J Clin Pharmacol       Date:  2005-01-27       Impact factor: 2.953

5.  Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension.

Authors:  Frank de Vries; Sander Pouwels; Madelon Bracke; Jan-Willem Lammers; Olaf Klungel; Hubert Leufkens; Tjeerd van Staa
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

Review 6.  Respirable microspheres for inhalation: the potential of manipulating pulmonary disposition for improved therapeutic efficacy.

Authors:  Masahiro Sakagami; Peter R Byron
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

7.  Towards a Quantitative Mechanistic Understanding of Localized Pulmonary Tissue Retention-A Combined In Vivo/In Silico Approach Based on Four Model Drugs.

Authors:  Anneke Himstedt; Clemens Braun; Sebastian Georg Wicha; Jens Markus Borghardt
Journal:  Pharmaceutics       Date:  2020-04-29       Impact factor: 6.321

8.  Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.

Authors:  Fabien Pillard; Michel Lavit; Valérie Lauwers Cances; Jacques Rami; Georges Houin; Alain Didier; Daniel Rivière
Journal:  Respir Res       Date:  2015-12-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.